Factors influencing patient decisions to initiate and discontinue subcutaneous testosterone pellets (Testopel) for treatment of hypogonadism

Journal of Sexual Medicine

Volumn 10, Issue 9, 2013, Pages 2326-2333

  Smith, Ryan P ^a   Khanna, Abhinav ^a   Coward, Robert M ^a   Rajanahally, Saneal ^a   Kovac, Jason R ^a   Gonzales, Marshall A ^a   Lipshultz, Larry I ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Hypogonadism; Patient Satisfaction; Subcutaneous Testosterone Pellets; Testosterone; Testosterone Replacement

Indexed keywords

TESTOPEL; TESTOSTERONE; UNCLASSIFIED DRUG;

ADULT; ANDROGEN THERAPY; ARTICLE; DRUG COST; DRUG EFFICACY; DRUG PELLET; DRUG SAFETY; HUMAN; HYPOGONADISM; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; PATIENT COMFORT; PATIENT DECISION MAKING; PRIORITY JOURNAL; TESTOSTERONE BLOOD LEVEL; TREATMENT OUTCOME; UROLOGY;

HYPOGONADISM; PATIENT SATISFACTION; SUBCUTANEOUS TESTOSTERONE PELLETS; TESTOSTERONE; TESTOSTERONE REPLACEMENT;

DECISION MAKING; DRUG COSTS; DRUG IMPLANTS; HEALTH CARE SURVEYS; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOGONADISM; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PATIENT SATISFACTION; PATIENTS; PHYSICIAN-PATIENT RELATIONS; QUESTIONNAIRES; RETROSPECTIVE STUDIES; TESTOSTERONE;

EID: 84883559843     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/jsm.12226     Document Type: Article

References (36)

1. Corona G, Lee DM, Forti G, O'Connor DB, Maggi M, O'Neill TW, Pendleton N, Bartfai G, Boonen S, Casanueva FF, Finn JD, Giwercman A, Han TS, Huhtaniemi IT, Kula K, Lean ME, Punab M, Silman AJ, Vanderschueren D, Wu FC. Age-related changes in general and sexual health in middle-aged and older men: Results from the European Male Ageing Study (EMAS). J Sex Med 2010;7:1362-1380.
2. Tajar A, Huhtaniemi IT, O'Neill TW, Finn JD, Pye SR, Lee DM, Bartfai G, Boonen S, Casanueva FF, Forti G, Giwercman A, Han TS, Kula K, Labrie F, Lean ME, Pendleton N, Punab M, Vanderschueren D, Wu FC. Characteristics of androgen deficiency in late-onset hypogonadism: Results from the European Male Aging Study (EMAS). J Clin Endocrinol Metab 2012;97:1508-1516.
3. Wang C, Nieschlag E, Swerdloff RS, Behre H, Hellstrom WJ, Gooren LJ, Kaufman JM, Legros JJ, Lunenfeld B, Morales A, Morley JE, Schulman C, Thompson IM, Weidner W, Wu FC. ISA, ISSAM, EAU, EAA and ASA recommendations: Investigation, treatment and monitoring of late-onset hypogonadism in males. Aging Male 2009;12:5-12.
4. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM. Testosterone therapy in men with androgen deficiency syndromes: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010;95:2536-2559.
5. Mulligan T, Frick MF, Zuraw QC, Stemhagen A, McWhirter C. Prevalence of hypogonadism in males aged at least 45 years: The HIM study. Int J Clin Pract 2006;60:762-769.
6. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2001;86:724-731.
7. Corona G, Mannucci E, Forti G, Maggi M. Hypogonadism, ED, metabolic syndrome and obesity: A pathological link supporting cardiovascular diseases. Int J Androl 2009;32:587-598.
8. Corona G, Monami M, Rastrelli G, Aversa A, Tishova Y, Saad F, Lenzi A, Forti G, Mannucci E, Maggi M. Testosterone and metabolic syndrome: A meta-analysis study. J Sex Med 2011;8:272-283.
9. Wu FC, Tajar A, Beynon JM, Pye SR, Silman AJ, Finn JD, O'Neill TW, Bartfai G, Casanueva FF, Forti G, Giwercman A, Han TS, Kula K, Lean ME, Pendleton N, Punab M, Boonen S, Vanderschueren D, Labrie F, Huhtaniemi IT, Group E. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med 2010;363:123-135.
10. Kelleher S, Conway AJ, Handelsman DJ. Blood testosterone threshold for androgen deficiency symptoms. J Clin Endocrinol Meitab 2004;89:3813-3817.
11. Korbonits M, Slawik M, Cullen D, Ross RJ, Stalla G, Schneider H, Reincke M, Bouloux PM, Grossman AB. A comparison of a novel testosterone bioadhesive buccal system, striant, with a testosterone adhesive patch in hypogonadal males. J Clin Endocrinol Metab 2004;89:2039-2043.
12. Bhasin S, Storer TW, Berman N, Yarasheski KE, Clevenger B, Phillips J, Lee WP, Bunnell TJ, Casaburi R. Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. J Clin Endocrinol Metab 1997;82:407-413.
13. Giltay EJ, Tishova YA, Mskhalaya GJ, Gooren LJ, Saad F, Kalinchenko SY. Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome. J Sex Med 2010;7:2572-2582.
14. Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto AM, Snyder PJ, Weber T, Berman N, Hull L, Swerdloff RS. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab 2004;89:2085-2098.
15. Cavender RK. Subcutaneous testosterone pellet implantation procedure for treatment of testosterone deficiency syndrome. J Sex Med 2009;6:21-24.
16. Conaglen JV, Conaglen HM. The effects of treating male hypogonadism on couples' sexual desire and function. J Sex Med 2009;6:456-463.
17. Bouloux PM, Legros JJ, Elbers JM, Geurts TB, Kaspers MJ, Meehan AG, Meuleman EJ. Effects of oral testosterone undecanoate therapy on bone mineral density and body composition in 322 aging men with symptomatic testosterone deficiency: A 1-year, randomized, placebo-controlled, dose-ranging study. Aging Male 2013;16:38-47.
18. Moskovic DJ, Katz DJ, Akhavan A, Park K, Mulhall JP. Clomiphene citrate is safe and effective for long-term management of hypogonadism. BJU Int 2012;110:1524-1528.
19. Katz DJ, Nabulsi O, Tal R, Mulhall JP. Outcomes of clomiphene citrate treatment in young hypogonadal men. BJU Int 2012;110:573-578.
20. Burnett-Bowie SA, Roupenian KC, Dere ME, Lee H, Leder BZ. Effects of aromatase inhibition in hypogonadal older men: A randomized, double-blind, placebo-controlled trial. Clin Endocrinol (Oxf) 2008;70:116-123.
21. McCullough AR, Khera M, Goldstein I, Hellstrom WJ, Morgentaler A, Levine LA. A multi-institutional observational study of testosterone levels after testosterone pellet (Testopel((R))) insertion. J Sex Med 2012;9:594-601.
22. Cavender RK, Fairall M. Subcutaneous testosterone pellet implant (Testopel) therapy for men with testosterone deficiency syndrome: A single-site retrospective safety analysis. J Sex Med 2009;6:3177-3192.
23. Jockenhovel F, Vogel E, Kreutzer M, Reinhardt W, Lederbogen S, Reinwein D. Pharmacokinetics and pharmacodynamics of subcutaneous testosterone implants in hypogonadal men. Clin Endocrinol (Oxf) 1996;45:61-71.
24. Kelleher S, Howe C, Conway AJ, Handelsman DJ. Testosterone release rate and duration of action of testosterone pellet implants. Clin Endocrinol (Oxf) 2004;60:420-428.
25. Pastuszak AW, Mittakanti H, Liu JS, Gomez L, Lipshultz LI, Khera M. Pharmacokinetic evaluation and dosing of subcutaneous testosterone pellets. J Androl 2012;33:927-937.
26. Kaminetsky JC, Moclair B, Hemani M, Sand M. A phase IV prospective evaluation of the safety and efficacy of extended release testosterone pellets for the treatment of male hypogonadism. J Sex Med 2011;8:1186-1196.
27. Kelleher S, Conway AJ, Handelsman DJ. A randomised controlled clinical trial of antibiotic impregnation of testosterone pellet implants to reduce extrusion rate. Eur J Endocrinol 2002;146:513-518.
28. Kelleher S, Conway AJ, Handelsman DJ. Influence of implantation site and track geometry on the extrusion rate and pharmacology of testosterone implants. Clin Endocrinol (Oxf) 2001;55:531-536.
29. Kelleher S, Turner L, Howe C, Conway AJ, Handelsman DJ. Extrusion of testosterone pellets: A randomized controlled clinical study. Clin Endocrinol (Oxf) 1999;51:469-471.
30. Conners W, Flinn K, Morgentaler A. Outcomes with the "V" implantation technique vs. standard technique for testosterone pellet therapy. J Sex Med 2011;8:3465-3470.
31. Pastuszak AW, Pearlman AM, Godoy G, Miles BJ, Lipshultz LI, Khera M. Testosterone replacement therapy in the setting of prostate cancer treated with radiation. Int J Impot Res 2012;25:24-28.
32. Institute of Medicine (U.S.). Committee on quality of health care in America. Crossing the quality chasm: A new health system for the 21st century. Washington, DC: National Academy Press; 2001.
33. Guay AT, Smith TM, Offutt LA. Absorption of testosterone gel 1% (Testim) from three different application sites. J Sex Med 2009;6:2601-2610.
34. Grober ED, Khera M, Soni SD, Espinoza MG, Lipshultz LI. Efficacy of changing testosterone gel preparations (Androgel or Testim) among suboptimally responsive hypogonadal men. Int J Impot Res 2008;20:213-217.
35. Rhoden EL, Morgentaler A. Symptomatic response rates to testosterone therapy and the likelihood of completing 12 months of therapy in clinical practice. J Sex Med 2010;7:277-283.
36. Fennell C, Sartorius G, Ly LP, Turner L, Liu PY, Conway AJ, Handelsman DJ. Randomized cross-over clinical trial of injectable vs. implantable depot testosterone for maintenance of testosterone replacement therapy in androgen deficient men. Clin Endocrinol (Oxf) 2010;73:102-109.